Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Frontiers in Oncology

Paola Rossi¹  Rosaria De Filippi²  Massimiliano Berretta³  Pasquale Vitale⁴  Raffaele Di Francia⁴  Giuseppina Ronga⁴  Sara Mele⁴  Antonio Pinto⁴  Stefania Crisci⁴ 

[1] Department of Biology and Biotechnology “L. Spallanzani,” University of Pavia, Pavia, Italy;Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy;Department of Medical Oncology, CRO National Cancer Institute, Aviano, Italy;Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione “G. Pascale” IRCCS, Naples, Italy;

关键词: anticancer mAbs;    tyrosine kinase inhibitors;    tailored therapy;    personalized medicine;    NHL;   

DOI  :  10.3389/fonc.2019.00443

来源: DOAJ

【 摘 要 】

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.

【 授权许可】

Unknown